MA46866A - Une forme cristalline d'un inhibiteur de magl - Google Patents

Une forme cristalline d'un inhibiteur de magl

Info

Publication number
MA46866A
MA46866A MA046866A MA46866A MA46866A MA 46866 A MA46866 A MA 46866A MA 046866 A MA046866 A MA 046866A MA 46866 A MA46866 A MA 46866A MA 46866 A MA46866 A MA 46866A
Authority
MA
Morocco
Prior art keywords
crystalline form
magl inhibitor
magl
inhibitor
crystalline
Prior art date
Application number
MA046866A
Other languages
English (en)
Other versions
MA46866B1 (fr
Inventor
Channing Rodney Beals
Jacqueline Lorayne Blankman
Cheryl A Grice
Kurt G Grimm
Todd K Jones
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of MA46866A publication Critical patent/MA46866A/fr
Publication of MA46866B1 publication Critical patent/MA46866B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/205—Radicals derived from carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
    • C07C57/13—Dicarboxylic acids
    • C07C57/15—Fumaric acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
MA46866A 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl MA46866B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662423126P 2016-11-16 2016-11-16
PCT/US2017/061875 WO2018093953A1 (fr) 2016-11-16 2017-11-15 Formes cristallines d'un inhibiteur de magl

Publications (2)

Publication Number Publication Date
MA46866A true MA46866A (fr) 2021-06-02
MA46866B1 MA46866B1 (fr) 2021-11-30

Family

ID=62145805

Family Applications (2)

Application Number Title Priority Date Filing Date
MA46866A MA46866B1 (fr) 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl
MA58133A MA58133B1 (fr) 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA58133A MA58133B1 (fr) 2016-11-16 2017-11-15 Une forme cristalline d'un inhibiteur de magl

Country Status (38)

Country Link
US (2) US11142517B2 (fr)
EP (2) EP3541807B1 (fr)
JP (2) JP7042548B2 (fr)
KR (1) KR102508739B1 (fr)
CN (2) CN115093382A (fr)
AU (1) AU2017361257B2 (fr)
BR (1) BR112019010003A2 (fr)
CA (1) CA3043610A1 (fr)
CL (1) CL2019001340A1 (fr)
CO (1) CO2019005045A2 (fr)
CR (1) CR20190242A (fr)
CY (2) CY1124870T1 (fr)
DK (1) DK3541807T3 (fr)
DO (1) DOP2019000120A (fr)
EA (1) EA201991086A1 (fr)
EC (1) ECSP19035171A (fr)
ES (2) ES2966939T3 (fr)
GE (2) GEP20237559B (fr)
HR (2) HRP20231697T1 (fr)
HU (2) HUE064559T2 (fr)
IL (1) IL266548A (fr)
JO (1) JOP20190109B1 (fr)
LT (1) LT3541807T (fr)
MA (2) MA46866B1 (fr)
MX (2) MX389459B (fr)
MY (1) MY199386A (fr)
NI (1) NI201900053A (fr)
PE (1) PE20191239A1 (fr)
PH (1) PH12019501068A1 (fr)
PL (2) PL3541807T3 (fr)
PT (1) PT3541807T (fr)
RS (2) RS62665B1 (fr)
SI (1) SI3541807T1 (fr)
SM (2) SMT202300494T1 (fr)
TN (1) TN2019000151A1 (fr)
UA (1) UA124585C2 (fr)
WO (1) WO2018093953A1 (fr)
ZA (1) ZA201903093B (fr)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ627750A (en) 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
CN109996790B (zh) 2016-09-19 2023-05-16 H.隆德贝克有限公司 哌嗪氨基甲酸酯及其制备和使用方法
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
CA3043609A1 (fr) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Formulations pharmaceutiques
US10927105B1 (en) 2017-05-23 2021-02-23 Lundbeck La Jolla Research Center, Inc. Pyrazole MAGL inhibitors
MY200738A (en) 2017-05-23 2024-01-13 H Lundbeck As Pyrazole magl inhibitors
UA126685C2 (uk) 2017-08-29 2023-01-11 Луннбек Ла-Холья Рісьоч Сенте, Інк. Сполуки, які є модуляторами magl, і способи їх отримання і застосування
MA52635A (fr) * 2018-05-15 2021-03-24 H Lundbeck As Inhibiteurs de magl
CA3106510A1 (fr) * 2018-07-19 2020-01-23 Pfizer Inc. Composes spiro heterocycliques utilises en tant qu'inhibiteurs de magl
MY210507A (en) 2018-08-13 2025-09-28 Hoffmann La Roche New heterocyclic compounds as monoacylglycerol lipase inhibitors
WO2020104494A1 (fr) 2018-11-22 2020-05-28 F. Hoffmann-La Roche Ag Nouveaux composés hétérocycliques
SG11202108008PA (en) * 2019-01-25 2021-08-30 H Lundbeck As Methods of treating disease with magl inhibitors
BR112021013917A2 (pt) * 2019-11-15 2022-05-24 H Lundbeck As Forma cristalina de um inibidor de magl, composição farmacêutica e uso
WO2021214550A1 (fr) * 2020-04-21 2021-10-28 H. Lundbeck A/S Synthèse d'un inhibiteur de monoacylglycérol lipase
WO2023092079A1 (fr) * 2021-11-19 2023-05-25 Bryant Cynthia W Utilisation de composés cannabinoïdes pour traiter des troubles gastro-intestinaux
IL313987A (en) 2021-12-29 2024-08-01 Psy Therapeutics Inc Inhibiting monoacylglycerol lipase (magl)
WO2023213854A1 (fr) 2022-05-04 2023-11-09 H. Lundbeck A/S Forme cristalline de 1,1,1,3,3,3-hexafluoropropan-2-yl (s)-1-(pyridazine-3-ylcarbamoyl)-6 azaspiro [2,5] octane-6-carboxylate en tant qu'inhibiteur de la monoacylglycérol lipase
CN117665187B (zh) * 2023-11-23 2024-08-16 宁波大红鹰药业股份有限公司 一种舒林酸中间体杂质的测定方法

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
ES2111065T5 (es) 1991-04-16 2005-06-16 Nippon Shinyaku Company, Limited Procedimiento para producir una dispersion solida.
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
WO1994008568A1 (fr) 1992-10-16 1994-04-28 Nippon Shinyaku Co., Ltd. Procede pour fabriquer des matrices de cire
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
KR19990014865A (ko) 1995-05-17 1999-02-25 피터 이. 브래이브맨 소장에서의 소화 및 흡수를 증진시키기 위한, 지방산을 함유한조성물들
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
AU2001225816B2 (en) 2000-12-18 2005-10-13 Novartis Ag Therapeutic combination of amlodipine and benazepril
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
DE60325834D1 (de) 2002-02-20 2009-03-05 Abbott Lab Kondensierte azabicyclischeverbindungen als inhibitoren des vanilloid-rezeptors 1 (vr1)
US7074805B2 (en) 2002-02-20 2006-07-11 Abbott Laboratories Fused azabicyclic compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
CA2598762A1 (fr) 2005-02-25 2006-08-31 F. Hoffmann-La Roche Ag Comprimes presentant une dispersibilite de substance medicamenteuse amelioree
ES2812250T3 (es) 2005-11-28 2021-03-16 Marinus Pharmaceuticals Inc Formulaciones de ganaxolona y procedimientos para la preparación y uso de las mismas
EP1938804A1 (fr) 2006-12-22 2008-07-02 Novartis AG Préparation pharmaceutique comprenant un antagoniste de neurokinine
FR2938341A1 (fr) 2008-11-13 2010-05-14 Galderma Res & Dev Modulateurs de la monoglyceride lipase dans le traitement de l'acne, d'une dermatite seborrheique ou de l'hyperseborrhee
WO2010063802A1 (fr) 2008-12-05 2010-06-10 Novartis Ag Cyclobutène-1,2-diones 3,4-disubstituées en tant qu'antagonistes de récepteur cxcr2
CN101530399B (zh) 2009-04-15 2011-01-26 江苏中兴药业有限公司 一种水飞蓟宾固体自乳化片
NZ627750A (en) * 2012-01-06 2016-11-25 Abide Therapeutics Inc Carbamate compounds and of making and using same
EP2828253A1 (fr) 2012-03-19 2015-01-28 Abide Therapeutics, Inc. Composés carbamates et leur procédé de fabrication et d'utilisation
WO2013159095A1 (fr) 2012-04-20 2013-10-24 Anderson Gaweco Modulateurs de ror et leurs utilisations
KR102396897B1 (ko) 2012-11-02 2022-05-13 버텍스 파마슈티칼스 인코포레이티드 Ｃｆｔｒ 매개된 질환의 치료를 위한 약제학적 조성물
TW201446286A (zh) 2013-01-31 2014-12-16 Gilead Pharmasset Llc 抗病毒化合物之固態分散調製劑
US9551036B2 (en) 2013-02-25 2017-01-24 Whitehead Institute For Biomedical Research Metabolic gene mesenchymal signatures and uses thereof
US9828379B2 (en) 2013-07-03 2017-11-28 Abide Therapeutics, Inc. Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereof
WO2015030854A1 (fr) 2013-08-27 2015-03-05 Gilead Pharmasset Llc Formulation de dispersion orale d'un composé antiviral
CN103893258B (zh) 2013-12-05 2017-09-29 人福医药集团股份公司 含有广金钱草总黄酮的口服固体制剂及其应用
WO2015164160A1 (fr) 2014-04-21 2015-10-29 Merck Sharp & Dohme Corp. Sels pharmaceutiques d'un antagoniste des récepteurs de l'orexine
WO2015179559A2 (fr) 2014-05-21 2015-11-26 Abide Therapeutics, Inc. Composés de pyrazole, procédés de production et utilisation
WO2016149401A2 (fr) 2015-03-18 2016-09-22 Abide Therapeutics, Inc. Carbamates de pipérazine et procédés de préparation et d'utilisation de ceux-ci
US10450302B2 (en) 2015-05-11 2019-10-22 Lundbeck La Jolla Research Center, Inc. Methods of treating inflammation or neuropathic pain
US10463753B2 (en) * 2016-02-19 2019-11-05 Lundbeck La Jolla Research Center, Inc. Radiolabeled monoacylglycerol lipase occupancy probe
PL3541807T3 (pl) 2016-11-16 2022-01-17 H. Lundbeck A/S Krystaliczna postać inhibitora magl
JOP20190105A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
CA3043609A1 (fr) 2016-11-16 2018-05-24 Abide Therapeutics, Inc. Formulations pharmaceutiques
JOP20190107A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)
JOP20190106A1 (ar) 2016-11-16 2019-05-09 Lundbeck La Jolla Research Center Inc مثبطات أحادي أسيل جليسرول ليباز (magl)

Also Published As

Publication number Publication date
EP3541807A4 (fr) 2020-04-22
SI3541807T1 (sl) 2022-01-31
PL3541807T3 (pl) 2022-01-17
EP3964503C0 (fr) 2023-11-08
HRP20211863T1 (hr) 2022-03-04
CL2019001340A1 (es) 2019-10-04
JP2022084717A (ja) 2022-06-07
NI201900053A (es) 2019-10-30
CN110291083B (zh) 2022-06-17
MX2022000249A (es) 2022-02-03
PE20191239A1 (es) 2019-09-16
DK3541807T3 (da) 2021-12-06
GEP20237559B (en) 2023-10-25
JP7042548B2 (ja) 2022-03-28
PT3541807T (pt) 2021-12-09
RS62665B1 (sr) 2021-12-31
US20220235037A1 (en) 2022-07-28
MA58133B1 (fr) 2024-02-29
MX389459B (es) 2025-03-20
EP3964503A1 (fr) 2022-03-09
PL3964503T3 (pl) 2024-04-02
RU2019116689A3 (fr) 2021-02-26
KR20190077561A (ko) 2019-07-03
AU2017361257B2 (en) 2022-02-10
EP3964503B1 (fr) 2023-11-08
CA3043610A1 (fr) 2018-05-24
JP7350117B2 (ja) 2023-09-25
CY1124870T1 (el) 2022-11-25
GEAP202315091A (en) 2023-05-10
RS65016B1 (sr) 2024-01-31
PH12019501068A1 (en) 2019-08-19
CO2019005045A2 (es) 2019-05-31
EP3541807B1 (fr) 2021-09-29
JOP20190109A1 (ar) 2019-05-09
HUE064559T2 (hu) 2024-03-28
LT3541807T (lt) 2021-12-27
CN115093382A (zh) 2022-09-23
US20200190063A1 (en) 2020-06-18
UA124585C2 (uk) 2021-10-13
NZ753241A (en) 2021-06-25
ECSP19035171A (es) 2019-05-31
SMT202100675T1 (it) 2022-01-10
RU2019116689A (ru) 2020-12-17
US11993588B2 (en) 2024-05-28
US11142517B2 (en) 2021-10-12
ZA201903093B (en) 2020-11-25
CR20190242A (es) 2019-07-09
ES2900016T3 (es) 2022-03-15
MY199386A (en) 2023-10-25
EA201991086A1 (ru) 2019-11-29
MA46866B1 (fr) 2021-11-30
CN110291083A (zh) 2019-09-27
TN2019000151A1 (en) 2020-10-05
SMT202300494T1 (it) 2024-01-10
CY1126586T1 (el) 2026-02-25
IL266548A (en) 2019-07-31
JP2019537596A (ja) 2019-12-26
WO2018093953A1 (fr) 2018-05-24
MX2019005767A (es) 2019-12-05
DOP2019000120A (es) 2019-09-30
BR112019010003A2 (pt) 2019-08-20
ES2966939T3 (es) 2024-04-25
AU2017361257A1 (en) 2019-05-30
JOP20190109B1 (ar) 2022-09-15
HUE056973T2 (hu) 2022-04-28
HRP20231697T1 (hr) 2024-03-15
EP3541807A1 (fr) 2019-09-25
KR102508739B1 (ko) 2023-03-09

Similar Documents

Publication Publication Date Title
EP3541807A4 (fr) Formes cristallines d'un inhibiteur de magl
MA47575A (fr) Composés inhibiteurs d'oga monocyclique
EP3431075A4 (fr) Forme galénique d'édaravone
EP3526328A4 (fr) Polythérapie pour l'inhibition de c3
MA41252A (fr) Formes solides d'un inhibiteur d'ask 1
EP3357153A4 (fr) Circuit d'attaque pour actionneur capacitif à haute tension
MA42606A (fr) Sels d'un inhibiteur de lsd1
MA47420A (fr) Composés inhibiteurs d'oga
IL260730B (en) Process for preparing terpinene-4-ol
EP3365344A4 (fr) Sel d'un inhibiteur d'egfr, forme cristalline correspondante et utilisations correspondantes
EP2969262A4 (fr) Compositions d'inhibition de corrosion
MA46972A (fr) Forme polymorphe de sépiaptérine
EP3415146A4 (fr) Inhibiteur de l'activation des inflammasomes
EP3449001A4 (fr) Inhibition de l'arnmi mir-22 par apt-110
MA49006A (fr) Inhibiteurs d'ip6k
EP3277757A4 (fr) Compositions pour l'inhibition de corrosion
EP3337485A4 (fr) Formes cristallines d'ibrutinib
EP3478477A4 (fr) Génération d'instructions de fabrication additive
EP3500898A4 (fr) Hélage d'un véhicule
MA46567A (fr) Formes cristallines de l'éravacycline
DK3286317T3 (da) Dynamin 2-inhibitor til behandlingen af duchennes muskeldystrofi
IL269695A (en) Compounds useful as inhibitors of alcat 1
MA48944A (fr) Forme cristalline de n-butyldéoxygalactonojirimycine
EP2970290A4 (fr) Forme cristalline d'un composé anxiolytique
MA43764A (fr) Inhibiteur monovalent de l'interaction hutnfr1